Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28523904 | 1.00 | CPB1 (0.58) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL15046656 | 1.00 | CPB1 (0.58) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL14392357 | 0.92 | EPHX1 (0.55) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL19515030 | 0.92 | EPHX1 (0.55) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL3883687 | 0.92 | EPHX1 (0.55) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL14368969 | 0.92 | EPHX1 (0.55) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL3883690 | 0.92 | EPHX1 (0.55) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL26253804 | 0.91 | EPHX1 (0.57) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL27667815 | 0.88 | CPB1 (0.56) | CPB1ALDH1A1GAATSHREPHX1 | |
| SCHEMBL21359175 | 0.87 | CPB1 (0.60) | CPB1ALDH1A1GAATSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115534-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2023-04-13 | — | — | US | disclosed |
| EP-4077283-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115534-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | CPB1 404/4885ALDH1A1 4760/4885GAA 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.